Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Novo Nordisk A/S · NCT07767175

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–55 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
142
US sites recruiting
1
Study start
August 12, 2026
Record last updated
September 4, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

Being studied: NNC0721-8060; Semaglutide; Placebo

Conditions: Overweight; Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Male or female (sex at birth).
  • Age 18-55 years (both inclusive) at the time of signing informed consent.
  • Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
  • Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.

Exclusion Criteria

  • Known or suspected hypersensitivity to study intervention(s) or related products.
  • Previous randomisation in this study.
  • History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.
  • Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.
  • Current participation (signed informed consent) in any other interventional clinical study.
  • Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.
  • Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.
  • Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole [mmol/mol]) at screening.

Recruiting US locations

Study contacts (from the official record)

  • Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
All weight loss studies in Kansas →
A First-in-human Research Study on How NNC0721-8060 Works in… (NCT07767175) | Bored Studies